- Bursa Uludag University Faculty of Medicine and Hospital - Internal Medicine specialization training (1986-1991) - Bursa Uludag University Faculty of Medicine and Hospital - Hematology subspecialty training (1991-1995) - Assistant Professor Doctor at Bursa Uludag University Faculty of Medicine and Hospital (1995-1997) - Associate Professor Doctor at Bursa Uludag University Faculty of Medicine and Hospital (1997-2003) - Professor Doctor at Bursa Uludag University Faculty of Medicine and Hospital (2003-2023) - Doruk Nilufer Hospital (2023-present) - MAIN RESEARCH AREAS: Pregnancy and hematologic diseases, Thrombosis and embolism, Primary thrombocytopenia, Bleeding disorders, Acute leukemia, Chronic myeloid leukemia, Chronic lymphocytic leukemia, Multiple myeloma, Non-Hodgkin lymphoma, Hodgkin lymphoma, Other lymphomas, Myelodysplastic syndromes, Polycythemia vera, Essential thrombocythemia, Myelofibrosis, Iron deficiency anemia - N/A

КУРСЫ

• Profesor Ridvan Ali, MD obtained his Medical Degree from the Cerrahpasa Faculty of Medicine, University of Istanbul, Turkey, in 1982. He completed his internal medicine and hematology training in Uludag University School of Medicine, Turkey. He awarded as assistant professor in 1995, associate professor in 1997 and professor in 2003. Since August 2023 he has been working in the Bursa Doruk Nilüfer Hospital. He is member of the several Turkish Associations of Hematology and American Society of Hematology (passive), European Association of Hematology (passive). He has placed on editorial board of several Turkish journals and reviewer for several international journals. He has authored or co-authored international and national journal publications. Scientific Publications - 81 papers in international journals - 150 papers in Turkish journals - 5 book chapters - 40 abstracts in international meetings - 200 abstracts in Turkish meetings Main Areas of Interest: - Chronic myeloid leukemia - Chronic lymphocytic leukemia - Lymphomas - Multiple myeloma - Myelodisplastic syndromes - Acute leukemias - Anemia - Primary thrombocytopenia - Thrombosis - Chronic Myeloprolative Neoplasms

СЕМИНАРИЯ

• Katıldığı Kurslar : 30 Katıldığı Kongre Ve Seminerler : 125

ULUSLARARASI YAYINLAR TOPLAM :  81 

1.    The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Saydam G, Ali R, Demir AM, Eskazan AE, Guvenc B, Haznedaroglu IC, Ozcan MA, Salim O, Sonmez M, Tuglular AT, Turgut M, Unal A, Aver B, Bozkurt S, Ozdengulsun B, Ilhan O.

Int J Hematol Oncol. 2022;11(1):IJH38. doi: 10.2217/ijh-2021-0010. 

2.    Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting.

Eşkazan AE, Ali R, Alnıgeniş E, Ayyıldız O, Haznedaroğlu İ, Kırkızlar O, Kurtoğlu E, Malhan S, Öksüz E, Polat Ö, Saydam G, Sönmez M, Toprak SK, Toptaş T, Turgut M.

Expert Rev Hematol. 2022;15(2):97-106. doi: 10.1080/17474086.2022.2044779.

3.    Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.

Soyer N, Ali R, Turgut M, Haznedaroğlu İC, Yilmaz Af, Aydoğdu İ, Pır A, Karakuş V, Özgür G, Kiş C, Ceran F, İlhan G, Özkan M, Aslaner M, İnce İ, Yavaşoğlu İ, Gediz F, Sönmez M, Güvenç B, Özet G, Kaya E, Vural F, Şahİn F, Töbü M, Durusoy Onmuş İr, Saydam G.

Turk J Med Sci. 2020 Dec 14. doi: 10.3906/sag-1812-70.

4.    Polycythemia vera: diagnosis, clinical course, and current management.

Büyükaşik Y, Ali R, Ar C, Turgut M, Yavuz S, Saydam G.

Turk J Med Sci. 2018 Aug 16;48(4):698-710. doi: 10.3906/sag-1806-43.

5.    Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial.                                                                                                                                

   Beksac M, Ali R, Ozcelik T, Ozcan M, Ozcebe O, Bayik M, Paydas S, Buyukasik, Ilhan O, Ozkalemkas F, Gurman G, Uysal A, Akan H, Soydan EA, Tunali A.                                              

 Leuk Res. 2011 Mar;35(3):340-5. doi: 10.1016/j.leukres.2010.07.005.

6.    Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. 

Ali R, Ozkalemkas F, Ozkocaman V, Yakut T, Nazlioglu HO, Budak F, Pekgoz M, Korkmaz S, Karkucak M, Ozcelik T, Tunali A.                                                                                                                

Int J Clin Oncol. 2009 Dec;14(6):545-50. doi: 10.1007/s10147-009-0884-5.                                                                                        

7.    Imatinib use during pregnancy and breast feeding: a case report and review of the literature.

Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, Yorulmaz H, Tunali A.

Arch Gynecol Obstet. 2009 Aug;280(2):169-75. doi: 10.1007/s00404-008-0861-7.

8.     Efficacy of bortezomib in combination chemotherapy on secondary plasmacell leukemia.

Ali R, Beksac M, Ozkalemkas F, Ozkocaman V, Ozkan A, Ozcelik T, Tunali A.

Leuk Lymphoma. 2007 Jul;48(7):1426-8.

9.    Extramedullary plasma cytomain volving the abdominal vessels and pancreas.

Ali R, Ozkalemkas F, Ozcelik T, Ozkan A, Ozkocaman V, Ozturk H, Kurt M, Sadikoglu Y, Elbuken-Ozer G, Tunali A.

Dig Dis Sci. 2007 Nov;52(11):3199-201.

10.    Invasive pulmonary aspergillosis in acute leukemia: current issues for pathogenesis, diagnosis and treatment.  

 Ali R,  Ozcelik T.

Current Respir Med Rev. 2006;2:3-13

11.  Superior vena cava syndrome: Initial presentation of acute myeloid leukemia (AML-M0) with near-tetraploidy+/TdT+/CD7+/CD34+/HLA-DR+.

Ali R, Ozkalemkas F, Yerci O, Ozcelik T, Gebitekin C, Ozkocaman V, Ozkan A, Budak F, Gulten T, Cetintas S, Tunali A.

LeukLymphoma. 2006 May;47(5):937-40.

 12. Superior vena cava syndrome: Initial presentation of acute myeloid leukemia (AML-M0) with near-tetraploidy+/TdT+/CD7+/CD34+/HLA-DR+.

Ali R, Ozkalemkas F, Yerci O, Ozcelik T, Gebitekin C, Ozkocaman V, Ozkan A, Budak F, Gulten T, Cetintas S, Tunali A.

LeukLymphoma. 2006 May;47(5):937-40.

13. Hydatid disease in acute leukemia: effect of anticancer treatment on echinococcosis.                  

 Ali R, Ozkalemkas F, Ozkocaman V, Ozcelik T, Akalin H, Ozkan A, Altundal Y, Tunali A.

Microbes Infect. 2005 Jul;7(9-10):1073-6.

14.   Pregnancy undertreatment of imatinib and successfull abor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.

Ali R, Ozkalemkaş F, Ozçelik T, Ozkocaman V, Ozan U, Kimya Y, Köksal N, Gülten T, Yakut T, Tunali A.

Leuk Res. 2005 Aug;29(8):971-3.

15. Idiopathic thrombocytopenic purpura in pregnancy: a single institutional experience with maternal and neonatal outcomes.

Ali R, Ozkalemkaş F, Ozçelik T, Ozkocaman V, Ozan U, Kimya Y, Köksal N, Bülbül-Başkan E, Develioğlu O, Tüfekçi M, Tunali A.  

Ann Hematol. 2003 Jun;82(6):348-52.